No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Household & Personal Products
Established in Osaka, Japan, in 1899, Rohto Pharmaceutical Co.,Ltd. is a global entity engaged in the development, manufacturing, and marketing of a diverse array of pharmaceutical goods, beauty products, and nutritional supplements. Their comprehensive product line includes various ophthalmic solutions such as eye drops, contact lens care products, and eye washes. For skincare, they offer facial treatments like cleansers, toners, and creams, in addition to specialized medicated preparations for the skin. The company's offerings also extend to internal medicines, encompassing digestive aids, herbal remedies, and dietary supplements. Furthermore, they supply over-the-counter medications and deliver beauty and health services via dedicated counters. The company rebranded from Yamada Pharmaceutical to Rohto Pharmaceutical Co.,Ltd. in September 1949.
www.rohto.co.jpNo one on the platform currently holds 4527.T.
No tracked institution reports a position in 4527.T as of their last filing.
No one on the platform has traded 4527.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.9% | 15.0% | 13.8% | — | — | — |
| Rev. Growth % | 11.4% | 13.7% | ||||
| Profit Margin % | 10.0% | 10.6% | 8.8% | |||
| Free Cash Flow Margin % | 10.6% | 9.4% | 8.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $371.0B | +9.5% | $159.62 | $144.52–$174.81 | — | 11 |
| 2028 | $389.6B | +5.0% | $169.45 | $156.86–$187.66 | — | 11 |
| 2029 | $406.9B | +4.5% | $178.02 | $167.24–$190.11 | — | 9 |
| 2030 | $425.7B | +4.6% | $195.50 | $181.11–$203.11 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $38.77 | $47.14 | +21.6% |
| 2026-05-13 | $30.36 | $26.41 | -13.0% |
| 2026-02-12 | $44.11 | $47.03 | +6.6% |
| 2025-11-13 | $26.10 | $27.20 | +4.2% |
| 2025-05-13 | $24.96 | $27.38 | +9.7% |
| 2025-02-12 | $49.09 | $52.09 | +6.1% |
| 2024-11-13 | $35.07 | $19.46 | -44.5% |
| -0.68% |
| $587.2B |
| — |
| 2501.TSapporo Holdings Limited | $1859.50 | -0.29% | $724.9B | — |
| 2809.TKewpie Corporation | $4527.00 | -0.94% | $617.3B | — |
Source: Financial Modeling Prep · peers by sector/industry